Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis.

Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis.
复制标题

DOI:
10.1089/10430340252792512
复制
发表时间:
2002-02
期刊:
影响因子:
4.2
通讯作者:
J. Woods;M. Amin;K. Katschke;M. Volin;J. Ruth;M. A. Connors;D. Woodruff;H. Kurata;K. Arai;G. Haines;Pawan Kumar;A. Koch
J. Woods;M. Amin;K. Katschke;M. Volin;J. Ruth;M. A. Connors;D. Woodruff;H. Kurata;K. Arai;G. Haines;Pawan Kumar;A. Koch
中科院分区:
医学2区
文献类型:
--
作者:
J. Woods;M. Amin;K. Katschke;M. Volin;J. Ruth;M. A. Connors;D. Woodruff;H. Kurata;K. Arai;G. Haines;Pawan Kumar;A. Koch

文献摘要

被引文献

相似文献

类风湿性关节炎(RA)是一种慢性自身免疫性炎症性疾病,其特征是滑膜血管翳形成、白细胞浸润和血管生成。腺病毒介导的白细胞介素-13(IL-13)的产生降低了体外RA滑膜组织移植模型中促炎介质的水平。为了在关节炎动物模型中评估这种方法,我们比较了关节内注射腺病毒产生大鼠IL-13(AxCArIL-13),对照病毒,以及大鼠踝关节接受磷酸盐缓冲盐水(PBS)在大鼠佐剂诱导的关节炎(AIA)中的作用。我们证明,IL-13水平通常是低的,在整个过程中的大鼠AIA的踝关节。我们表明,在关节炎发作前给予AxCArIL-13显著降低了踝关节周长、爪体积、骨破坏、多形核细胞(PMN)数量、血管数量和踝关节中单核细胞趋化蛋白(MCP)-1水平。当作为治疗给药至发炎的踝关节时,AxCArIL-13降低关节指数评分、爪体积、骨破坏、血管形成、肿瘤坏死因子-α(TNF-α)水平以及单核细胞、淋巴细胞和PMN的量。因此,增加IL-13水平显着改善大鼠AIA的过程中,这表明类似的策略治疗人类RA值得进一步研究。
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by synovial pannus formation, leukocyte infiltration, and angiogenesis. Adenoviral production of interleukin-13 (IL-13) reduces levels of proinflammatory mediators in an explant model of RA synovial tissue in vitro. To assess this approach in an animal model of arthritis, we compared intra-articular injections of an adenovirus producing rat IL-13 (AxCArIL-13), a control virus, and rat ankles receiving phosphate-buffered saline (PBS) in rat adjuvant-induced arthritis (AIA). We demonstrate that IL-13 levels are normally low in ankles throughout the course of rat AIA. We show that administration of AxCArIL-13 before arthritis onset significantly reduces ankle circumference, paw volume, bony destruction, the number of polymorphonuclear cells (PMNs), the quantity of blood vessels, and levels of monocyte chemoattractant protein (MCP)-1 in ankles. When administered as a treatment to inflamed ankles, AxCArIL-13 decreases articular index scores, paw volumes, bony destruction, vascularization, tumor necrosis factor-alpha (TNF-alpha) levels, and the quantity of monocytes, lymphocytes, and PMNs. Thus, increasing IL-13 levels significantly ameliorates the course of rat AIA, suggesting that similar strategies for the treatment of human RA are worthy of further study.